DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ALKEM LABORATORIES LTD. (ALKEM) share price today?

ALKEM LABORATORIES LTD. (ALKEM) is trading at ₹5,563 on the NSE, down 2.56% on the day. Source: DocStoX.

What is the PE ratio of ALKEM LABORATORIES LTD.?

ALKEM LABORATORIES LTD. has a price-to-earnings (PE) ratio of 28.9 in the Healthcare sector.

What is the market capitalisation of ALKEM LABORATORIES LTD.?

ALKEM LABORATORIES LTD. has a market capitalisation of approximately ₹66,516 crore.

ALKEM LABORATORIES LTD.

F&O

ALKEM·NSE·Healthcare

₹5,563.00▼ -146.00 (-2.56%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 200NIFTY 500NIFTY MIDCAP 150

Day₹5539.00

₹5709.00

52W₹4739

₹593469%

Open

₹5709.00

High

₹5709.00

Low

₹5539.00

Prev Close

₹5709.00

Volume

70.6K

VWAP

₹5581.96

Snapshot

Key fundamentals

Market Cap

₹66,516 Cr

P/E Ratio

28.90Fair

P/B Ratio

4.76

EPS

₹192.51

Book Value

₹1156.00

ROE

18.90%Strong

ROCE

21.00%Efficient

Dividend Yield

0.76%

Debt / Equity

0.15Low

Face Value

₹2.00

52W High

₹5933.50

52W Low

₹4738.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹1,709

▼ 69.3%downside

Trading at ₹5,563 — 69% above our estimate

BearFair valueBull

₹1,453₹1,709₹2,238

/100

Business quality — Solid

Growth 66Profitability 74Efficiency 33Valuation 73

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Capital is working hard (ROCE 21%)
Profit growing 33% a year

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

19% ROE fading to 12% over ~10 yrs, on ₹1156 book

₹1,562

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹2,238

Analyst target

No analyst coverage

—

Blended fair value₹1,709

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 21%)
Profit growing 33% a year

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

28.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

18.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.15Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹66,516 Cr

P/B

4.76

EPS

₹192.51

Div Yield

0.76%

What changed

Recent changes

Foreign investors+0.3% stake last quarter
Domestic institutions+1.3% stake last quarter
Promoters-1.50% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 28.9×

Growth

Steady

+8% rev CAGR

Profitability

Excellent

18.9% ROE

Financial health

Rock solid

D/E 0.15

Momentum

N/A

No technicals

Today

Trading activity

Delivery %54.8%

Turnover₹3941.09L Cr

Trades12,381

VWAP₹5581.96

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+8.3%

+10.7%

10Y

+11.6%

Profit

+32.7%

+7.8%

10Y

+12.1%

EPS

+32.7%

+7.8%

10Y

+12.0%

Profile

Pros

Company has been maintaining a healthy dividend payout of 26.3%

Watch-outs

Cons

Promoter holding has decreased over last quarter: -1.50%
The company has delivered a poor sales growth of 10.7% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 1.50 pts; foreign investors bought 0.27 pts; domestic institutions added 1.25 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

50%

Promoter

Promoters

49.7%-1.50

Public

17.3%0.00

FII / FPI

10.4%+0.27

DII

22.6%+1.25

Quarterly trend

Ownership over time

Q1 FY27

Promoter49.70%

FII10.42%

DII22.64%

Public17.25%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O